FDA Law Blog: Drug Discovery

FEBRUARY 2, 2023

Since 1962, the FD&C Act has authorized FDA to require that sponsors of clinical trials submit data from “preclinical tests (including tests on animals)” in order to demonstrate that their drug is safe enough to advance to testing in humans. adequate to justify the proposed clinical testing.” 21 U.S.C. §

Animal Testing 64

Animal Testing Biosimilars Cell Based Assays FDA 64

Drug Target Review

JULY 6, 2023

Animal testing plays a significant role in pre-clinical research and therefore requires the use of millions of animals. million scientific procedures involving live animals were carried out in 2020. million scientific procedures involving live animals were carried out in 2020. In Britain, 2.88 In Britain, 2.88

Animal Testing 105

Animal Testing Drugs Clinical Trials Clinical Research 105

Drug Target Review

SEPTEMBER 10, 2024

This approach also requires an early identification of molecular liabilities and rheological properties, generally using research-grade material supply, in conjunction with in-silico modelling to de-risk drug formulation. FDA no longer has to require animal testing for new drugs. References: 1 Wadman M.

Drug Development 64

Drug Development Clinical Supply Production FDA 64

The Premier Consulting Blog

APRIL 25, 2023

This act amends the Federal Food, Drug, and Cosmetic Act (FFDCA), which applies to new drugs, and the Public Health Service Act, which applies to biosimilars. As a result, the FDA is now required to consider alternatives to animal testing, such as in vitro , in silico , and in chemico tests and models.

FDA 52

FDA Animal Testing Pharmacokinetics Small Molecule 52